<qa>  How many menopausal patients were enrolled in the randomized, double-blinThe benefit-risk-balance of the isopropanolic Cimicifuga racemosa extract iCR is compared with tibolone in menopausal symptoms treatment. The randomized, double-blind, controlled 3-month study in 5 centres of 3 cities in China enrolled 244 menopausal patients aged 40 - 60 years and with a Kupperman Menopause Index KMI equal or more than 15. The participants were assigned to either iCR corresponding to 40 mg crude drugday n122 or tibolone 2,5 mgday n122 orally. The primary endpoint is the combination of the Mann-Whitney values MWV of the KMI and the frequency of adverse events benefit-risk balance at end of treatment. 